An open-label, randomized, controlled trial on the benefit of β-hydroxy-β-methyl butyrate, l-arginine, l-glutamine combination beverages and locomotion training as supportive care for the treatment of unresectable hepatocellular carcinoma using lenvatinib: A pilot study (HELLO study).
- 2025-02
- RCT · n = 20
- Clinical nutrition ESPEN 65
- Atsushi Naganuma
- Fujio Makita
- Rie Sugimoto
- Masahiro Kikuchi
- Kiyoshi Furuta
- Satoru Iwamoto
- Ryotaro Sakamori
- Hirotaka Kouno
- Keisuke Ario
- Hiroshi Yatsuhashi
- PubMed: 39675424
- DOI: 10.1016/j.clnesp.2024.12.005
- High evidence
- Clinical
a slight retention of L3-SMI values in the intervention group compared with that in the control group was observed (96.5 % vs. 89.9 %, p = 0.407).
- Effect
- Beneficial
- Effect size
- Small
- Significant
- No